ObesitySwitch TZPNCT07889453

Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide

An observational study of Obesity and Type 2 Diabetes (T2D), run by LMC Diabetes & Endocrinology Ltd. at 1 site in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The goal of this retrospective observational study is to evaluate the effectiveness of switching from injectable semaglutide to tirzepatide in adults living with type 2 diabetes (T2D) and, descriptively, in a smaller cohort of adults living with obesity without diabetes, using clinical data from the LMC Diabetes… Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Obesity, Type 2 Diabetes (T2D)
What is being tested?: Tirzepatide
Type of treatment: Injection or infusion
How many people: 650 participants
Where: 1 siteCanada
Study dates: 15 Oct 2026to Jun 2027
Phase: Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: The study populations will include adults living with T2D and adults living with obesity without diabetes, who switched from injectable semaglutide to tirzepatide, or adults living with T2D who were prescribed injectable semaglutide and did not switch to tirzepatide.

Who may be able to join

Age 18 years old or older
A clinical diagnosis of T2D ≥ 1 year
Baseline HbA1c ≥ 7.5%
≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
≥ one body weight value up to 6 months (+ 90 days) prior to index date
Initiated injectable semaglutide or switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025

Show all 19Show fewer

Use of injectable semaglutide for ≥ 3 months for both the control and switch cohort
If using real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM), CGM use for ≥ 3 months
Seen by an LMC endocrinologist in the last 18 months as of the query date
Informed data consent for their medical record data to be used for research purposes
Age 18 years old or older
BMI ≥ 30 kg/m2
Baseline HbA1c < 6.5%
≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
≥ one body weight value up to 6 months (+ 90 days) prior to index date
Initiated injectable semaglutide and switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025
Use of injectable semaglutide for ≥ 3 months
Seen by an LMC endocrinologist in the last 18 months as of the query date
Informed data consent for their medical record data to be used for research purposes

Who cannot join

Clinical diagnosis of type 1 diabetes or latent autoimmune diabetes in adults
Prior use of tirzepatide
Were pregnant at the time of semaglutide initiation or semaglutide-to-tirzepatide switch or became pregnant during follow-up period
Bariatric surgery

Trial locations and contacts

1 site in 1 country.

Canada1 site

LMC Diabetes & Endocrinology Ltd.
Toronto, Ontario, M4G 3E8

Other trials in Canada

About this study

Official title: Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide: A Retrospective Study of the LMC Diabetes Registry

The study has two co-primary objectives: 1) to assess change in body weight from baseline to follow-up (6-12 months) among adults living with T2D who switched from injectable semaglutide to tirzepatide, and 2) to assess change in body weight over the same period among adults living with obesity without diabetes who switched.

Secondary objectives will compare changes in body mass index (BMI), estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (uACR), waist circumference, blood pressure, alanine transaminase (ALT), lipids, and insulin use from baseline to follow-up between adults living with T2D who switched to tirzepatide and a propensity score-matched group of adults living with T2D who continued semaglutide.

Conditions: Obesity, Type 2 Diabetes (T2D)
Being tested: Tirzepatide
Keywords: tirzepatide, semaglutide, type 2 diabetes, obesity, real-world evidence
Medical subject headings: Obesity, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

TirzepatideDrug
Only the T2D and obesity (non-T2D) Tirzepatide switch cohorts will be using this intervention

Study groups in NCT07889453
Study group	Role	What they receive
T2D Switch TZP Cohort		adults living with T2D who switched from injectable semaglutide to tirzepatide Receives: Drug: Tirzepatide
Obesity Switch TZP Cohort		adults living with obesity without diabetes, who switched from injectable semaglutide and to tirzepatide Receives: Drug: Tirzepatide
T2D SEMA Cohort		adults living with T2D who were prescribed injectable semaglutide and did not switch to tirzepatide

What is being measured

The primary outcome is the main question the study is designed to answer.

Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort
Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with T2D who switched from injectable semaglutide to tirzepatide during the index period.
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Body Weight at 12 Months - Obesity Switch TZP Cohort
Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with obesity (non-diabetes) who switched from injectable semaglutide to tirzepatide during the index period.
Measured: Baseline to follow-up (6-12 months)

Secondary outcomes (20)

Change from Baseline in HbA1c at 12 Months - T2D Cohort
Change in HbA1c among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Percent Body Weight at 12 Months - T2D Cohort
Change in percent body weight (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Body Mass Index (BMI) at 12 Months - T2D Cohort
Change in BMI (kg/m^2) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Blood Pressure at 12 Months - T2D Cohort
Change in blood pressure (mmHg) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Waist Circumference at 12 Months - T2D Cohort
Change in waist circumference (cm) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) at 12 Months - T2D Cohort
Change in eGFR (ml/min/1.73m^2) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Urine Albumin-to-Creatinine Ratio (uACR) at 12 Months - T2D Cohort
Change in uACR (mg/mmol) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Alanine Transaminase (ALT) at 12 Months - T2D Cohort
Change in ALT (U/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Lipids at 12 Months - T2D Cohort
Change in lipids (mmol/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Insulin use (none, basal only, basal-bolus) - T2D Cohort
insulin use among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Number of Antihyperglycemic Agents (AHAs) at 12 Months - T2D Cohort
number of AHAs at 6-12 months follow-up among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Follow-up (6-12 months)
Proportion of Individuals who Discontinued Treatment during Follow-up Period (6-12 Months) - T2D Cohort
Proportion of individuals who discontinued treatment during follow-up period among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Percent time in range (TIR) at 12 Months - T2D Cohort
Percent TIR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using continuous glucose monitoring (CGM)
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Percent Time Above Range (TAR) at 12 Months - T2D Cohort
Change in percent TAR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Percent Time Below Range (TBR) at 12 Months - T2D Cohort
Change in percent TBR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Percent TBR in Level 2 Hypoglycemia at 12 Months - T2D Cohort
Change in percent TBR level 2 (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Percent Time In Tight Range (TITR) at 12 Months - T2D Cohort
Change in percent TITR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Mean glucose at 12 Months - T2D Cohort
Change in mean glucose (mmol/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)
Change from Baseline in Glycemic Variability at 12 Months - T2D Cohort
Change in glucose variability (SD and CV) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)
Percent sensor capture at 12 Months - T2D Cohort
Percent sensor capture (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM
Measured: Baseline to follow-up (6-12 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 Oct 2026Jun 2027

First posted22 Oct 2026
Study start15 Oct 2026
Primary completionDec 2026 (estimated)
Study completionJun 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for ObesityStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Retrospective
Enrolment: 650 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07889453
Sponsor's protocol ID: Switch SEMA TZP
Acronym: Switch TZP
Status last verified: Oct 2026
First submitted: 15 Oct 2026
Last updated: 22 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: This is an observational study using registry data. IPD will not be shared.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 3
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Obesity, Childhood, Insulin Resistance
Active, not recruiting
tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity
Obesity
Not yet recruitingPhase 2
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Insulin Resistance, Obesity
Active, not recruitingPhase 1/2
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
Overweight and Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity

All Obesity trials